Iron therapy for renal anemia: how much needed, how much harmful?
Open Access
- 1 April 2007
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (4) , 480-489
Abstract
Iron deficiency is the most common cause of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in end-stage renal disease (ESRD) patients. Iron deficiency can easily be corrected by intravenous iron administration, which is more effective than oral iron supplementation, at least in adult patients with chronic kidney disease (CKD). Iron status can be monitored by different parameters such as ferritin, transferrin saturation, percentage of hypochromic red blood cells, and/or the reticulocyte hemoglobin content, but an increased erythropoietic response to iron supplementation is the most widely accepted reference standard of iron-deficient erythropoiesis. Parenteral iron therapy is not without acute and chronic adverse events. While provocative animal and in vitro studies suggest induction of inflammation, oxidative stress, and kidney damage by available parenteral iron preparations, several recent clinical studies showed the opposite effects as long as intravenous iron was adequately dosed. Thus, within the recommended international guidelines, parenteral iron administration is safe. Intravenous iron therapy should be withheld during acute infection but not during inflammation. The integration of ESA and intravenous iron therapy into anemia management allowed attainment of target hemoglobin values in the majority of pediatric and adult CKD and ESRD patients.Keywords
This publication has 110 references indexed in Scilit:
- Sodium ferric gluconate complex maintenance therapy in children on hemodialysisPediatric Nephrology, 2006
- Low incidence of adverse events following 90‐minute and 3‐minute infusions of intravenous iron sucrose in children on erythropoietinActa Paediatrica, 2005
- Sodium ferric gluconate complex therapy in anemic children on hemodialysisPediatric Nephrology, 2005
- Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysisPediatric Nephrology, 2004
- Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized studyPediatric Nephrology, 2004
- The management of anemia in pediatric peritoneal dialysis patientsPediatric Nephrology, 2003
- Chronic dialysis in children and adolescents. The 2001 NAPRTCS Annual ReportPediatric Nephrology, 2002
- Erythropoietin treatment in children with renal failurePediatric Nephrology, 1999
- Immunologic function and survival in hemodialysis patientsKidney International, 1998
- Safety Aspects of Parenteral Iron in Patients with End-Stage Renal DiseaseDrug Safety, 1997